vishnevskiipavuh.blogspot.com
HOW IT WILL MAKE MONEY: PrognosDx planes to make money through development and commercialization of its tests and servicez and through strategic corporate partnershipss and technology licensing agreements with pharmaceutical and lifescience companies. BUSINESS OR TECHNOLOGY IT COULrD DISRUPT: Existing commercial diagnostic products and drug discoveryu anddevelopment tools. MANAGEMENT TEAM: Founder and CEO Kamraj Tahamtanzadeh has more than 16 yearz of experience in the biotechnology including as director of business developmeny in the translational diagnosticf business unit at Ventanz MedicalSystems Inc., proteome lab specialist at Beckmanh Coulter Inc.
and business development manager atMetriGenix Inc. Acting Chietf Scientific OfficerCarl T. Yamashirk has more than 14 yearsof R&D experiencer in developing molecular diagnostic tests and is now associatee director of technology development at the Biodesign Institutes at Arizona State Michael Becker, president and CEO of MD Becker Partners LLC, is the company’s acting chief operating officer. Beckere has more than 15 yearsof experience, includingh as CEO at VioQuest Pharmaceuticals Inc. and at AxCell Biosciences, a subsidiaryt of Cytogen Corp. BOARD OF Dr. Siavash K.
Kurdistani, an assistangt professor in biological chemistry at UCLA who is the inventotr ofthe company’s technology; Dr. David B. Seligson, assistantr professor and director of biomarker innovations and the tissue microarray core facilituyat UCLA; Dr. Mehdi Kamarei, chief of the departmentg of urology at Kaiser Permanentw inSanta Clara. PARTNERSHIPS, COLLABORATIONS: PrognosDd has an exclusive worldwide license to the patent rights for its productfthrough UCLA. MARKET SIZE BEING PURSUED: The market opportunit for cancer diagnostics exceedsseveral billion. LIKELtY COMPETITORS: Genomic Health Inc., Myriad Genetics Inc.
and othedr providers of predictive although the company said these may also represent strategix partnersgoing forward.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment